-
Tytuł:
-
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.
-
Autorzy:
-
Ciurea A; Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland .
Papagiannoulis E; SCQM Foundation, Zurich, Switzerland.
Bürki K; Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
von Loga I; SCQM Foundation, Zurich, Switzerland.
Micheroli R; Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
Möller B; Department of Rheumatology, Clinical Immunology and Allergy, Inselspital University Hospital Bern, Bern, Switzerland.
Rubbert-Roth A; Division of Rheumatology, Kantonsspital Sankt Gallen, Sankt Gallen, Switzerland.
Andor M; Private Rheumatology Practice, Uster, Switzerland.
Bräm R; Swiss Ankylosing Spondylitis Association, Zurich, Switzerland.
Müller A; Rheumaliga Schweiz, Zurich, Switzerland.
Dan D; Department of Rheumatology, CHUV, Lausanne, Switzerland.
Kyburz D; Department of Rheumatology, University Hospital Basel, Basel, Switzerland.
Distler O; Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
Scherer A; SCQM Foundation, Zurich, Switzerland.
Finckh A; Department of Rheumatology, Geneva University Hospitals, Geneve, Switzerland.
-
Źródło:
-
Annals of the rheumatic diseases [Ann Rheum Dis] 2021 Feb; Vol. 80 (2), pp. 238-241. Date of Electronic Publication: 2020 Sep 22.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : BMJ
Original Publication: London : H.K. Lewis
-
MeSH Terms:
-
COVID-19*
Symptom Flare Up*
Arthritis, Psoriatic/*physiopathology
Arthritis, Rheumatoid/*physiopathology
Spondylarthropathies/*physiopathology
Adult ; Aged ; Antirheumatic Agents/therapeutic use ; Arthritis, Psoriatic/drug therapy ; Arthritis, Rheumatoid/drug therapy ; Cohort Studies ; Disease Progression ; Female ; Humans ; Male ; Medication Adherence/statistics & numerical data ; Middle Aged ; Mobile Applications ; Patient Reported Outcome Measures ; Rheumatic Diseases/physiopathology ; Rheumatology ; SARS-CoV-2 ; Smartphone ; Spondylarthropathies/drug therapy ; Switzerland
-
Contributed Indexing:
-
Keywords: ankylosing; arthritis; epidemiology; psoriatic; rheumatoid; spondylitis
-
Substance Nomenclature:
-
0 (Antirheumatic Agents)
-
Entry Date(s):
-
Date Created: 20200923 Date Completed: 20210122 Latest Revision: 20230829
-
Update Code:
-
20240105
-
DOI:
-
10.1136/annrheumdis-2020-218705
-
PMID:
-
32963052
-
Objectives: To investigate whether the transient reduction in rheumatology services imposed by virus containment measures during the COVID-19 pandemic was associated with disease worsening in axial spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA).
Methods: Patient-reported disease activity assessed during face-to-face visits and/or via a smartphone application were compared between three periods of each 2 months duration (before, during and after the COVID-19-wave) from January to June 2020 in 666 patients with axSpA, RA and PsA in the Swiss Clinical Quality Management cohort.
Results: The number of consultations dropped by 52%, whereas the number of remote assessments increased by 129%. The proportion of patients with drug non-compliance slightly increased during the pandemic, the difference reaching statistical significance in axSpA (19.9% vs 13.2% before the pandemic, p=0.003). The proportion of patients with disease flares remained stable (<15%). There was no increase in mean values of the Bath Ankylosing Disease Activity Index, the Rheumatoid Arthritis Disease Activity Index-5 and the Patient Global Assessment in patients with axSpA, RA and PsA, respectively.
Conclusion: A short interruption of in-person patient-rheumatologist interactions had no major detrimental impact on the disease course of axSpA, RA and PsA as assessed by patient-reported outcomes.
Competing Interests: Competing interests: AC reports personal fees from Abbvie, Celgene, Eli-Lilly, Merck Sharp & Dohme, Novartis and Pfizer, outside the submitted work. OD reports personal fees from Abbvie, Amgen, Lilly and Pfizer, outside the submitted work. RM reports personal fees from Gilead, Eli-Lilly and Abbvie, outside the submitted work.
(© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
